A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
A phase 2 trial of Lifileucel in melanoma and skin cancer, run by Iovance Biotherapeutics, Inc., active and no longer recruiting.
Overview
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is a phase 2 interventional study registered as NCT07288203 by Iovance Biotherapeutics, Inc., with 100 participants planned, started 2025-11-28 and due to reach its primary completion in 2032-12. Interventions recorded: Lifileucel. Conditions listed: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Shares Iovance Biotherapeutics, Lifileucel.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Iovance Biotherapeutics, Melanoma.
- TrialStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Shares Iovance Biotherapeutics, Melanoma.
- TrialC-144-01
Shares Iovance Biotherapeutics, Lifileucel, Melanoma.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Iovance Biotherapeutics, Melanoma.
- IdeaUse patient organoids to check a cell therapy will work before infusing it
Shares Iovance Biotherapeutics, Lifileucel.
- PairingPD-1 failure → TIL therapy
Shares Lifileucel, Melanoma.
- PersonInge Marie Svane
Shares Lifileucel, Melanoma.